7.88

1.87% -0.16

Corvus Pharmaceuticals Inc (CRVS)

Overview News Price History Option Chain Financials Discussions Forecast

Corvus Pharmaceuticals Inc stock is traded at $7.88, with a volume of 709.33K. It is down -1.87% in the last 24 hours and up +9.74% over the past month. Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Previous Close:

$8.04

Open:

$7.89

24h Volume:

709.33K

Relative Volume:

0.91

Market Cap:

$589.41M

Revenue:

Net Income/Loss:

$-27.03M

P/E Ratio:

-14.07

EPS:

-0.56

Net Cash Flow:

$-23.97M

1W Performance:

+0.38%

1M Performance:

+9.74%

6M Performance:

+117.96%

1Y Performance:

-13.30%

1-Day Range:

$7.52

$7.99

1-Week Range:

$7.46

$8.44

52-Week Range:

$2.54

$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name

Corvus Pharmaceuticals Inc

Sector

Healthcare (1139)

Industry

Biotechnology (635)

Phone

(650) 900-4520

Address

863 MITTEN ROAD, BURLINGAME, CA

Employee

Twitter

Next Earnings Date

2025-03-25

Latest SEC Filings

CRVS's Discussions on Twitter

Compare CRVS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRVS Corvus Pharmaceuticals Inc	7.91	599.09M	0	-27.03M	-23.97M	-0.56
VRTX Vertex Pharmaceuticals Inc	425.69	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	641.80	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	432.61	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	822.11	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	183.82	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-13-25	Initiated	Barclays	Overweight
Jan-02-25	Initiated	H.C. Wainwright	Buy
Aug-18-23	Initiated	Oppenheimer	Outperform
Dec-01-21	Resumed	Jefferies	Buy
May-27-21	Initiated	Cantor Fitzgerald	Overweight
Feb-10-21	Downgrade	Mizuho	Buy → Neutral
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Credit Suisse	Outperform
Apr-18-16	Initiated	Guggenheim	Buy

View All

Corvus Pharmaceuticals Inc Stock (CRVS) Latest News

09:30 AM

Corvus to present final data on T cell lymphoma drug at ASH meeting - Investing.com

09:30 AM

09:15 AM

Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikesTrade Signal Summary & High Win Rate Trade Tips - newser.com

09:15 AM

09:02 AM

Corvus Pharma (NASDAQ: CRVS) to present soquelitinib 1/1b T‑cell lymphoma data at ASH - Stock Titan

09:02 AM

07:12 AM

Corvus Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com

07:12 AM

06:17 AM

How to build a dashboard for Corvus Pharmaceuticals Inc. stockDip Buying & Stepwise Trade Signal Implementation - newser.com

06:17 AM

Nov 02, 2025

What machine learning models say about Corvus Pharmaceuticals Inc.Weekly Trend Report & Technical Entry and Exit Tips - newser.com

Nov 02, 2025

Why Corvus Pharmaceuticals Inc. stock could benefit from AI revolutionJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com

Nov 02, 2025

Is Corvus Pharmaceuticals Inc. forming a bottoming base2025 Big Picture & Verified Entry Point Signals - newser.com

Nov 02, 2025

What momentum indicators show for Corvus Pharmaceuticals Inc. stockJuly 2025 Volume & High Accuracy Swing Entry Alerts - newser.com

Nov 02, 2025

Should you wait for a breakout in Corvus Pharmaceuticals Inc.July 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com

Nov 02, 2025

Nov 01, 2025

What technical models suggest about Corvus Pharmaceuticals Inc.’s comebackWeekly Investment Summary & Safe Capital Growth Tips - newser.com

Nov 01, 2025

Real time social sentiment graph for Corvus Pharmaceuticals Inc.Quarterly Trade Report & High Win Rate Trade Tips - newser.com

Nov 01, 2025

Is Corvus Pharmaceuticals Inc. stock a defensive play in 2025July 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com

Nov 01, 2025

Combining price and volume data for Corvus Pharmaceuticals Inc.Quarterly Earnings Report & Fast Exit and Entry Trade Guides - newser.com

Nov 01, 2025

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth - Sahm

Nov 01, 2025

Oct 31, 2025

Corvus Pharmaceuticals Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView

Oct 31, 2025

Corvus Pharmaceuticals (CRVS) Expected to Announce Earnings on Tuesday - MarketBeat

Oct 31, 2025

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times

Oct 31, 2025

Oct 30, 2025